BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 11003880)

  • 1. [Clinical manifestations and biological markers in the natural history of HIV-1 infection in vertically infected children. Longitudinal study].
    Resino S; Bellón JM; Jiménez JL; Gurbindo D; Muñoz-Fernández MA
    An Esp Pediatr; 2000 Feb; 52(2):138-47. PubMed ID: 11003880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prognostic markers of survival in infants younger than 12 month of age vertically infected by human immunodeficiency virus].
    Resino S; Jiménez JL; Gurbindo D; Muñoz-Fernández MA
    Med Clin (Barc); 1999 Nov; 113(15):561-6. PubMed ID: 10605680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early neurodevelopmental markers predictive of mortality in infants infected with HIV-1.
    Llorente A; Brouwers P; Charurat M; Magder L; Malee K; Mellins C; Ware J; Hittleman J; Mofenson L; Velez-Borras J; Adeniyi-Jones S;
    Dev Med Child Neurol; 2003 Feb; 45(2):76-84. PubMed ID: 12578232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Primary infection in vertically infected HIV-1 infants: biological characteristics of isolated virus, viral load and CD4 t-lymphocytes].
    Resino García S; Jiménez Fuentes JL; Gurbindo Gutiérrez D; Navarro J; Abad ML; Muñoz-Fernández MA
    An Esp Pediatr; 1999 Nov; 51(5):469-74. PubMed ID: 10652796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral studies of mothers with human immunodeficiency virus infection at delivery and their infants in the first 3 days of life.
    Sison AV; Brandt CD; Rakusan TA; Wientzen R; Fuccillo DA; Sever JL
    Pediatr AIDS HIV Infect; 1996 Oct; 7(5):325-30. PubMed ID: 11361490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV.
    Palombi L; Marazzi MC; Voetberg A; Magid NA
    AIDS; 2007 Jul; 21 Suppl 4():S65-71. PubMed ID: 17620755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival pattern among infants born to human immunodeficiency virus type-1 infected mothers and uninfected mothers in Harare, Zimbabwe.
    Nathoo K; Rusakaniko S; Zijenah LS; Kasule J; Mahomed K; Mashu A; Choto R; Mbizvo M
    Cent Afr J Med; 2004; 50(1-2):1-6. PubMed ID: 15490717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women.
    Lavreys L; Baeten JM; Chohan V; McClelland RS; Hassan WM; Richardson BA; Mandaliya K; Ndinya-Achola JO; Overbaugh J
    Clin Infect Dis; 2006 May; 42(9):1333-9. PubMed ID: 16586394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Survival and disease progression in 251 patients with HIV-1 infection. Study of p24 antigen and viral burden as prognosis makers. Their value at 4 years of follow-up].
    Rubio Caballero M; Rubio Rivas C; Nogués Biau A; Falguera Sacrest M; Manonelles Fernández A
    An Med Interna; 2001 Oct; 18(10):517-20. PubMed ID: 11766280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of depressive symptoms at ART initiation on HIV clinical progression and mortality: implications in clinical practice.
    Villes V; Spire B; Lewden C; Perronne C; Besnier JM; Garré M; Chêne G; Leport C; Carrieri MP; Le Moings V;
    Antivir Ther; 2007; 12(7):1067-74. PubMed ID: 18018765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy.
    Weiser B; Philpott S; Klimkait T; Burger H; Kitchen C; Bürgisser P; Gorgievski M; Perrin L; Piffaretti JC; Ledergerber B;
    AIDS; 2008 Feb; 22(4):469-79. PubMed ID: 18301059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The prognostic markers of survival and progression in HIV-1 infection. A study of CD4+ lymphocytes, antigen p24 and viral load during 3 years in a cohort of 251 patients].
    Rubio Caballero M; Nogués Biau A; Falguera Sacrest M; Puig Ganau T; Lecha N; Rubio Rivas C
    An Med Interna; 2000 Oct; 17(10):533-7. PubMed ID: 11109648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of immunologic long-term nonprogression in HIV-infected children: implications for initiating therapy.
    Paul ME; Mao C; Charurat M; Serchuck L; Foca M; Hayani K; Handelsman EL; Diaz C; McIntosh K; Shearer WT;
    J Allergy Clin Immunol; 2005 Apr; 115(4):848-55. PubMed ID: 15806009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors predicting the persistence of genital human papillomavirus infections and PAP smear abnormality in HIV-positive and HIV-negative women during prospective follow-up.
    Branca M; Garbuglia AR; Benedetto A; Cappiello T; Leoncini L; Migliore G; Agarossi A; Syrjänen K;
    Int J STD AIDS; 2003 Jun; 14(6):417-25. PubMed ID: 12816671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A refined symptom-based approach to diagnose pulmonary tuberculosis in children.
    Marais BJ; Gie RP; Hesseling AC; Schaaf HS; Lombard C; Enarson DA; Beyers N
    Pediatrics; 2006 Nov; 118(5):e1350-9. PubMed ID: 17079536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early treatment for HIV-infected infants.
    Cadman J
    GMHC Treat Issues; 1997; 11(7-8):34-5. PubMed ID: 11364653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction in perinatal transmission and mortality from human immunodeficiency virus after intervention with zidovudine in Barbados.
    St John AM; Kumar A; Cave C
    Pediatr Infect Dis J; 2003 May; 22(5):422-6. PubMed ID: 12792382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gender differences in perinatal HIV acquisition among African infants.
    Taha TE; Nour S; Kumwenda NI; Broadhead RL; Fiscus SA; Kafulafula G; Nkhoma C; Chen S; Hoover DR
    Pediatrics; 2005 Feb; 115(2):e167-72. PubMed ID: 15687425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor-alpha and nitric oxide in vertically HIV-1-infected children: implications for pathogenesis.
    González-Nicolás J; Resino S; Jiménez JL; Alvarez S; Fresno M; Muñoz-Fernández MA
    Eur Cytokine Netw; 2001; 12(3):437-44. PubMed ID: 11566624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.
    Murillas J; Rimola A; Laguno M; de Lazzari E; Rascón J; Agüero F; Blanco JL; Moitinho E; Moreno A; Miró JM;
    Liver Transpl; 2009 Sep; 15(9):1133-41. PubMed ID: 19718643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.